But ironically, the company has benefited from winning tenders to counter the impact of the avian flu pandemic which has ...

Moving to the operating highlights for CSL Behring on slide 6. The underlying fundamentals of plasma collection remain ... across the whole pipe. We pay them in accordance with the contract ...

CSL consistency isn’t winning over investors, Ryan Stokes explains the new dump truck dance, and Macquarie’s return on equity ...

Vaccine aversion in the US has put a hole in CSL revenues in the first half, with the company saying the flu season is shaping up to be the worst in 15 to 20 years. But ironically, the company has ...

ASX health stocks have fallen this week as Chemist Warehouse hits the bourse through its merger with Sigma Healthcare.

Due to the planned CSL transition, Plasma revenue declined 9% in the quarter ... and that's just a function of pay-for-performance and the fact that we're not where we need to be across the ...

These shares are highly rated by analysts at Bell Potter. But why? The post 2 high-quality ASX 200 blue chip shares to buy with $2,000 in February appeared first on The Motley Fool Australia.

CSL is one of three Tier 1 plasma therapy companies that benefit from an oligopoly in a highly consolidated market. All the players are vertically integrated as plasma sourcing is a key constraint ...

Pharmaceuticals company CSL on Tuesday reported a 3% rise in first-half profit, benefiting from further growth in its main blood-plasma business.